- Stifel 2024 Immunology and Inflammation Virtual Summit on
Tuesday, September 17, 2024 , at2:00 p.m. ET . - TD Cowen’s Chronic Urticaria Summit on
Friday, September 20, 2024 , at11:00 a.m. ET .
A live webcast of each presentation will be available by visiting the Investors & Media section of Blueprint Medicines’ website at http://ir.blueprintmedicines.com. A replay of the webcasts will be archived on Blueprint Medicines’ website for 30 days following each presentation.
About Blueprint Medicines
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT ®/AYVAKYT ® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the